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Abstract
Background: ONO-5334 is a cathepsin K inhibitor that induced bone mineral density (BMD) gain in a phase II study
in postmenopausal osteoporosis patients. Even though the antiresorptive effect could only be monitored in the
morning during the study, simulation can allow the antiresorptive effect to be assessed over 24 h, with assessment
of the relationship to BMD gain.
Methods: Inhibition of the serum C-telopeptide of type I collagen (sCTX) level at doses of ONO-5334 of 100 mg
once daily (QD), 300 mg QD, and 50 mg twice daily (BID) was simulated using plasma ONO-5334 pharmacokinetic
(PK) data for repeated dose administration in a phase I study and corresponding sCTX inhibition from the PK-
pharmacodynamic (PK/PD) relationship. sCTX was selected because it has a high signal-to-noise ratio compared to
other telopeptides. A negative sigmoidal shape for the PK/PD relationship between plasma ONO-5334 and sCTX
levels was obtained in our previous study.
Results: The simulated sCTX inhibition reached >99% of the maximal inhibitory effect (Emax) at 0.5 h in all treatment
groups, and decreased to <80% Emax at 8 and 12 h at 50 mg BID and 100 mg QD, respectively. However, sCTX
inhibition at 300 mg QD was maintained at ≥82% Emax over 24 h. The mean sCTX inhibition rates for 24 h at 100 mg
QD, 300 mg QD and 50 mg BID were 63, 95 and 80% Emax, respectively. There was a positive linear relationship by
treatment group between mean sCTX inhibition over 24 h and observed BMD gain in the phase II study.
Conclusion: The dose response for BMD with ONO-5334 at 100 and 300 mg QD and higher BMD gain at 50 mg BID
vs. 100 mg QD can be explained by sCTX inhibition over 24 h. The simulation gave the antiresorptive effect of ONO-
5334 over 24 h and allowed prediction of BMD gain due to ONO-5334.
Trial registration: The registration number in The European Union Clinical Trials Register is 2007–002417-39. The date
of registration was August 31, 2007.
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Background
Osteoporosis is defined as a systemic skeletal disease char-
acterized by low bone mass and microarchitectural deteri-
oration of bone tissue, with a consequent increase in bone
fragility and susceptibility to fracture [1]. The disease is
characterized by an imbalance in skeletal turnover such that
bone resorption exceeds bone formation, thereby leading to
a reduction in overall bone mass [2]. Osteoporosis is usually
diagnosed based on bone mineral density (BMD), and sev-
eral biochemical markers are used to monitor bone resorp-
tion and bone formation. Drugs for osteoporosis are
classified as antiresorptive drugs that inhibit bone resorp-
tion, such as bisphosphonates, and anabolic agents that
stimulate bone formation, such as parathyroid hormone
[3]. Bisphosphonates are widely used first-line osteoporosis
agents due to fracture prevention by BMD increase and
prolonged antiresorptive effect after withdrawal [4].
Cathepsin K, a member of the papain cysteine protease
superfamily, is released by osteoclasts and degrades colla-
gen of bone [5]. Genetic evidence indicates a critical role
of cathepsin K in bone resorption in humans and mice
[6–8]. Cathepsin K releases type I collagen crosslinks such
as N-telopeptides of type I collagen (NTX) and C-telopep-
tides of type I collagen (CTX), which are widely used as
diagnostic biomarkers for evaluation of osteoporosis [9–
11]. Therefore, several cathepsin K inhibitors have been
examined as potential therapy for osteoporosis [12–14].
ONO-5334 is an orally available cathepsin K inhibitor
with established efficacy for increasing BMD and proven
safety in a 2-year phase II study in osteoporosis (the
OCEAN study) [15–17]. In earlier phase I studies, ONO-
5334 decreased serum CTX (sCTX) in a dose-dependent
manner. Plasma ONO-5334 reached a maximum (Cmax)
within 1.5 to 2 h of dosing and thereafter decreased in a
biphasic manner, with a rapid initial phase followed by a
slower phase. In repeated administration, the plasma
ONO-5334 level just before the next dose (trough)
reached steady state in 2 days after the first administra-
tion. Chemically, ONO-5334 is an α-amino acid derivative
with a ketone, which differs from another cathepsin K in-
hibitor, odanacatib, an aliphatic nitrile [18, 19]. These ca-
thepsin K inhibitors have similar efficacy in clinical and
non-clinical studies [15, 16, 20–24], but the pharmacoki-
netic (PK) profiles were differ, with odanacatib developed
as a once weekly treatment [18, 25].
The OCEAN study was a randomized, double-blind, pla-
cebo- and active-controlled parallel-group trial performed
to investigate the efficacy and safety of 100 mg once daily
(QD), 300 mg QD and 50 mg twice daily (BID) ONO-5334
immediate release (IR) tablets [16, 17]. ONO-5334 300 mg
QD was chosen because phase I data suggested that
≥300 mg ONO-5334 showed a maximum suppressive ef-
fect on sCTX, and that 300 mg ONO-5334 maintained the
suppressive effect on sCTX for 24 h after administration.
ONO-5334 100 mg QD was added for evaluation of the
dose response. ONO-5334 50 mg BID was chosen to com-
pare the efficacy and safety of two regimens with a 100 mg
total daily dose, to assess the potential for development of a
slow release (SR) formulation. ONO-5334 increased BMD
at all measured sites at 50 mg BID and 300 mg QD in the
trial. A dose of 100 mg QD had less efficacy for increasing
BMD compared to 50 mg BID and 300 mg QD. These
findings suggest that a higher trough concentration of
ONO-5334, rather than a higher Cmax, is more important
for BMD increase. The drug was administered in the even-
ing in the QD groups, and bone turnover markers were
assessed only in the morning, based on bone resorption
markers showing rhythmic variations and peaking at night
[26, 27]. Therefore, evaluation of the antiresorptive effect
over 24 h and its relationship to BMD was limited in the
OCEAN study. It was also difficult to calculate the antire-
sorptive effect over 24 h in phase I studies of ONO-5334 IR
formulations because of limited sampling points for detec-
tion of significant changes in bone resorption markers.
In contrast, ONO-5334 SR formulations most likely
maximize the potency of ONO-5334 by reducing Cmax
and increasing exposure around the trough [28]. In
addition, the flat PK profile of ONO-5334 SR may
minimize the lag-time between PK and pharmacodynamic
(PD) inhibition of bone resorption markers. Therefore,
ONO-5334 SR provided a better evaluation of the PK/PD
relationship in our previous study [29]. In an analysis ex-
cluding circadian variation of bone resorption markers, the
plasma levels of bone resorption markers and ONO-5334
were fitted with sigmoidal maximal inhibitory effect (Emax)
models, simply reflecting inhibition of cathepsin K. Further-
more, Eastell et al. clearly showed that changes in sCTX in-
hibition with ONO-5334 SR morning vs. evening dosing
parallel changes in the PK profile, highlighting a clear link
between PK levels and antiresorptive effects [30].
Even though the antiresorptive effect could only be
monitored at one point in the morning in the OCEAN
study, simulation can allow the antiresorptive effect to be
assessed for 24 h and may provide a better assessment of
the relationship of this effect with BMD increase. sCTX
has the highest signal-to-noise ratio among serum and
urinary NTX and CTX bone resorption markers [29]. In
this post-hoc analysis, the duration of antiresorptive ef-
fects, sCTX inhibition, and the relationship between anti-
resorptive effects and increases in BMD were investigated
in postmenopausal patients with osteoporosis.
Methods
Studies from which data were used
PK data at 50 mg BID, 100 mg QD and 300 mg QD were
used from the 15-day multiple-dosing cohort in a phase 1
study of ONO-5334 IR tablets (MAD study, n = 96) [31].
The MAD study was a randomized, double-blind, single-
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center study conducted at the Kendle Clinical Pharmacol-
ogy Unit, Utrecht, The Netherlands, from April to Novem-
ber 2006 (EudraCT: not applicable). The sigmoidal
relationship (Emax model) between plasma ONO-5334
concentrations and sCTX inhibition was taken from a study
using SR tablets of ONO-5334 (PKPD study, n = 10) [29].
The PKPD study was a phase 1, 2-part (4- and 2-way
crossover), open-label, randomized trial conducted at
Pharmaceutical Profiles, Ruddington, Nottingham, United
Kingdom, from January 2008 to April 2008 (European
Union Clinical Trials Register [EudraCT]: 2007–005206-47).
Data for sCTX inhibition and increase in BMD after 1 year
of treatment were taken from the OCEAN study (n = 285)
[16]. This study was a randomized, double-blind, multi-
center study conducted at 13 sites in six European countries
from December 2007 to August 2009 (EudraCT: 2007–
002417-39, ClinicalTrials.gov Identifier: NCT00532337).
The timing of 1 year was the end of the administration
period in the original OCEAN study and the last point for
PK data. Summaries of the two earlier phase I studies and
the OCEAN study are given in Additional file 1.
In all studies, the protocol and consent form were
reviewed and approved by an independent ethics com-
mittee prior to study initiation. Inclusion criteria for the
MAD and PKPD studies were healthy postmenopausal
females aged 45 to 75 years old with a body mass index
of 19 to 32 kg/m2 [28, 31]. All participants had cessation
of menstruation for more than 1 year before inclusion in
the trials. The OCEAN study included postmenopausal
women aged 55 to 75 years old with osteoporosis or
osteopenia with one fragility fracture (at the start of the
study), but otherwise in good general health [16].
Patients had cessation of menstruation for more than
5 years before inclusion in the trial. Osteoporosis was
defined as a T-score ≤ −2.5 and osteopenia as a
T-score ≤ −1 and > − 2.5 at the lumbar spine or total
hip. Patients with urinary CTX <200 mg/mmol creatinine
were excluded in the OCEAN study.
Measurement of the plasma ONO-5334 concentration
Plasma ONO-5334 was determined by a liquid
chromatography-tandem mass spectrometry with a lower
limit of quantification of 0.02 ng/mL [18, 29]. The precision
of the ONO-5334 assay was <15% (coefficient of variation)
and the accuracy was within 15% of the actual value. In the
50 mg BID group in the MAD study, ONO-5334 was
administered at 12-h dose intervals on days 1 to 14, and QD
on day 15 (in the morning) to allow determination of
terminal clearance similarly to other regimens. Complete
PK data were available on days 1 and 15. A steady state
plasma ONO-5334 concentration was reached on day 15;
therefore, PK data from 0 to 12 h after dosing on day 15
were used and data from 12 to 24 h were substituted by
values from 0 to 12 h.
Measurement of the sCTX concentration
The level of sCTX was determined by a CrossLaps
enzyme-linked immunosorbent assay (ELISA) at Charles
River Laboratories (Edinburgh, UK) [16, 28]. Blood sam-
ples were collected in the morning after overnight fast-
ing in the OCEAN study, but collected under a fed
condition in the PKPD study. All CTX values used in
simulations were higher than the lower limit of detection
and the bottom of the standard curve for the assay.
Simulation of sCTX levels from plasma ONO-5334
concentrations
PK data from the MAD study and the relationship be-
tween plasma ONO-5334 levels and sCTX inhibition in
healthy postmenopausal women obtained from the
PKPD study were used in simulation of the antiresorp-
tive effect of ONO-5334 [29, 31]. Our previous PK data
for 14 days after repeated administration were also used
in the simulation. sCTX inhibition for doses and regi-
mens in the OCEAN study were simulated using plasma
ONO-5334 levels and the sigmoidal Emax model in the
PKPD study (Fig. 1). The sigmoidal Emax model was fit-
ted to data using log-transformed ONO-5334 plasma
concentrations and effects on sCTX inhibition, using the
following equation [32].
Effect ¼ E0 þ
Emax  C
r
ECr50 þ C
r
where C is the plasma ONO-5334 concentration, the
baseline effect (E0) is 0.9%, the effect span (Emax) is
−54.0%, the half-maximal effective concentration of
ONO-5334 (EC50) is 2.07 ng/mL, and the sigmoidicity fac-
tor (Hill constant, γ) is 2.07 for a negative change [29].
Mean sCTX inhibition over 24 h was calculated from the
area under the sCTX inhibition (%Emax) curve (AUC)
from 0 to 24 h after ONO-5334 administration, which was
determined using the trapezoidal method. The mean
sCTX inhibition (%Emax) over 24 h was calculated by
dividing AUC by 24 h. The duration of sCTX inhibition
over 24 h was evaluated for ≥90%, ≥70, ≥50 and ≥30%
Emax using time intersections in the simulated sCTX in-
hibition (%Emax) plot. The 95% confidence interval (CI)
was calculated for sCTX inhibition (%Emax) at 24 h after
administration, but not for time-related analysis such as
AUC and duration of sCTX inhibition.
Relationship of sCTX inhibition and increase in BMD in
the OCEAN study
The relationship of sCTX inhibition for 24 h and the
mean increase in BMD for the lumbar spine (L1-L4) and
total hip after 1 year of treatment in the OCEAN study
were analyzed. BMD in the OCEAN study was measured
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using dual-energy X-ray absorptiometry (DXA) (Prodigy,
GE Lunar, Madison, WI, USA) [16]. DXA images ob-
tained at study sites were sent to a central site for image
analysis (Synarc A/S, Zweigniederlassung, Hamburg,
Germany). Linear regression analysis was used to evalu-
ate correlations of mean sCTX inhibition (%Emax) over
24 h and BMD increases using Pearson correlation ana-
lysis (GraphPad Prism Software Inc., San Diego, CA),
with significance defined as p < 0.05. The OCEAN study
continued for 2 years of treatment with assessment of
bone resorption markers and BMD [16, 17], but the last
available PK data were 1 year after administration.
Results
Baseline characteristics
Age, weight, sCTX and other parameters at baseline in
the MAD, PKPD and OCEAN studies are shown in Table
1. All studies were conducted in European countries and
included only postmenopausal Caucasian women. Mean
ages ranged from 60.6 to 65.3 years and mean baseline
weights ranged from 65.4 to 71.1 kg, with slightly higher
values in the MAD and PKPD studies than in the OCEAN
study. Mean sCTX ranged from 0.550 to 0.898 ng/mL.
Simulated sCTX inhibition based on plasma ONO-5334
concentration
In accord with the rapid increase of the plasma
ONO-5334 concentration, complete sCTX inhibition
(≥99% Emax) was achieved 0.5 h after administration
in all treatment groups (Figs. 2 and 3). From 1.5 to
2 h after administration, plasma ONO-5334 concen-
trations reached Cmax in the 100 mg QD, 300 mg
QD and 50 mg BID groups and were 14, 56, and 4
times higher than the concentration required for 99%
Emax, respectively. After Cmax, sCTX inhibition fell
in accord with the rapid decrease in ONO-5334, and
Fig. 1 Simulation of serum CTX (sCTX) inhibition in the OCEAN study. Plasma ONO-5334 concentrations in postmenopausal women were
measured in the MAD study [31]. Plasma ONO-5334 concentrations at doses of 50 mg BID, 100 mg QD and 300 mg QD were converted into
simulated sCTX inhibition using a sigmoidal Emax model from a PK/PD study [29]. Simulated sCTX inhibition over 24 h for doses and regimens
used in the OCEAN study (100 mg QD, 300 mg QD, and 50 mg BID) were then calculated [16]. Data for 100 mg QD is used as an illustrative
example. BMD: bone mineral density
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was <80% Emax at 100 mg QD and 50 mg BID at 12
and 8 h after administration, respectively. sCTX in-
hibition at 100 mg QD decreased to 12% Emax (95%
CI: 0–50%) at 24 h after administration, but sCTX in-
hibition with 50 mg BID was 43% Emax (95% CI:
18–74%) at 12 h after the first dose and increased
again at 12 h after the second dose in one day. sCTX
inhibition at 300 mg QD was maintained at >98%
Emax at 12 h after administration, and decreased to
82% Emax (95% CI: 24–100%) at 24 h. The duration
of sCTX inhibition over 24 h was longer at 50 mg
BID than at 100 mg QD for ≥90, ≥70, ≥50 and ≥30%
Emax (Fig. 4), despite the total daily ONO-5334 dose
being the same. The mean sCTX inhibition rates for
24 h at 100 mg QD, 300 mg QD and 50 mg BID
were 63, 95 and 80% Emax, respectively.
Comparison of simulated sCTX inhibition with observed
data in the OCEAN study
Next, we compared simulated sCTX inhibition at 12 h
after administration with observed sCTX inhibition in
the OCEAN study [16]. The simulated sCTX inhibition
rates at 100 mg QD, 300 mg QD and 50 mg BID were
35, 53 and 24% (66, 100 and 45% Emax), respectively.
The observed sCTX inhibition rates (standard deviation)
Table 1 Baseline Characteristics of the Study Population
Study MADa PKPDb OCEANd
Subjects/Patients Postmenopausal
women
Postmenopausal
women
Postmenopausal women with osteoporosis or
osteopenia
Number of subjects/ patients 27 10 278
Race 100% Caucasian 100% Caucasian 100% Caucasian
Age (Mean (SD), year) 60.6 (5.7) 63.2 (4.7) 65.3 (4.8)
Weight (Mean (SD), kg) 69.8 (7.4) 71.1 (9.8) 65.4 (9.8)
Height (Mean (SD), cm) 165.2 (5.0) 160.3 (6.0) 160.1 (5.9)
BMI (Mean (SD), kg/m2) 25.6 (2.4) 27.6 (2.7) 25.5 (3.7)
Serum CTX (Mean (SD), ng/mL) 0.550 (0.209) 0.898 (0.171)c 0.739 (0.249)
Urine CTX (Mean (SD), μmol/mmol
creatinine)
215 (91) 361 (165) 296 (128)
aOnly 50 mg BID, 100 mg QD and 300 mg QD groups in 15-day cohort. The original study was reported by Nagase et al. [31]
bValue of all predose [28]
cBaseline data of the first period
dFull analysis set in the OCEAN study [16]
Fig. 2 Plasma ONO-5334 concentrations following administration and those required for different levels of sCTX inhibition. Plasma ONO-5334
concentrations at 100 mg QD, 300 mg QD and 50 mg BID in the MAD study are shown. At 50 mg BID, plasma ONO-5334 concentrations
between 12 and 24 h after administration are substituted by values between 0 and 12 h. ONO-5334 concentrations required for sCTX inhibition
of 20, 50, 80 and 99% Emax are indicated. The plasma ONO-5334 concentration in the MAD study was reported by Nagase et al. [29]
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for 1 year treatment in the OCEAN study were 24%
(40%), 44% (38%) and 29% (41%), respectively.
Relationship between simulated sCTX inhibition and
increase in BMD
The relationships between simulated sCTX inhibition
over 24 h and observed increases in BMD of the lumbar
spine and total hip in the OCEAN study at 1 year are
shown in Fig. 5. BMD increases at both measured sites
were positively correlated with sCTX inhibition over
24 h. The maximum BMD increases (100% Emax for
24 h) at 1 year were calculated by linear regression to be
4.85% in the lumbar spine and 3.05% in the total hip.
Discussion
Simulated sCTX inhibition quickly reached >99% Emax
at 0.5 h at all doses, but then fell below 80% Emax at
100 mg QD and 50 mg BID, but not at 300 mg QD. The
mean sCTX inhibition rates over 24 h at 100 mg QD,
300 mg QD and 50 mg BID were 63, 95 and 80% Emax,
respectively. The longest sCTX inhibition occurred with
300 mg QD, followed in order by 50 mg BID and
100 mg QD. The observed increases in BMD at the lum-
bar spine and total hip in the OCEAN study showed
strong relationships with mean sCTX inhibition over
24 h. Taken together, these data show that the mean
antiresorptive effects of ONO-5334 over one day at
100 mg QD and 50 mg BID were <90% Emax. However,
300 mg QD gives almost maximal potential of 96%
Emax for antiresorptive effect. These results show that
simulation of antiresorptive effect over 24 h allows pre-
diction of BMD increases due to ONO-5334.
All three clinical studies used in this post-hoc analysis
included only postmenopausal Caucasian women. The
mean age of the patients in the OCEAN study was
slightly higher than in the MAD study, and the mean
Fig. 3 Simulated % Emax for sCTX inhibition over 24 h after ONO-5334 administration. Each symbol depicts sCTX inhibition obtained from the
Emax equation using the plasma ONO-5334 concentrations shown in Fig. 2. Emax is the predicted maximum drug effect as 53.1% sCTX inhibition
Fig. 4 Duration of simulated % Emax for sCTX inhibition over 24 h evaluated for the following categories of % Emax: ≥90, ≥70, ≥50 and ≥30%
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body weight in the OCEAN study was 7% lower than in
the MAD study. Plasma ONO-5334 levels in the
OCEAN study were comparable to those in the MAD
study (Additional file 2). There were differences in base-
line levels of bone resorption markers among studies,
but these levels do not seem to influence the antiresorp-
tive effect of cathepsin K inhibitors [16, 25]. Conse-
quently, the slight differences in baseline characteristics
were considered not to be clinically relevant or to have
significantly affected the outcome of the current analysis.
Therefore, it was considered appropriate to estimate the
antiresorptive effect of ONO-5334 in the OCEAN study
based on data from the MAD and PKPD studies.
The timing of administration also differed among
studies. ONO-5334 was administered in the morning in
the MAD and PKPD studies, but the QD groups re-
ceived ONO-5334 in the evening in the OCEAN study.
PK is influenced by variation of physiological functions
with time of day [33, 34]. Among these factors, gastric
pH may influence absorption of ONO-5334 because the
solubility of ONO-5334 is high at acidic pH. Gastric pH
transiently increases from pH 2 to pH 4 after a meal
[35], although PK parameters, Cmax and AUC of ONO-
5334 do not differ significantly in postprandial adminis-
tration compared with a fasted state [18]. Dissolution of
IR tablets is rapid (50% dissolution in vitro in <0.25 h).
Therefore, the difference in timing of administration
with ONO-5334 was unlikely to have significantly influ-
enced the PK. However, the timing of administration
may influence antiresorptive effects due to circadian
rhythms in bone turnover, which reach a peak during
the night/early morning and a nadir in the late afternoon
[26, 27]. Eastell et al. showed that changes in sCTX in-
hibition with ONO-5334 SR in morning vs. evening
dosing parallel changes in PK [30]. In addition, the sig-
moidal Emax model of sCTX with ONO-5334 SR was
similar under fed and fasted conditions [29]. Overall,
these limitation in differences in PK are unlikely to have
significantly influenced the simulation of levels of bone
resorption markers.
This post-hoc analysis showed that the mean antire-
sorptive effect over 24 h had a significant positive rela-
tionship with observed increases in BMD in the OCEAN
study. It is difficult to explain why the increase in BMD
at 50 mg BID was higher than that at 100 mg QD from
the observed sCTX and PK data in the OCEAN study,
in which there was no marked difference in sCTX be-
tween the two groups at 12 months. However, the simu-
lation of antiresorptive effect at 50 mg BID clearly
showed higher sCTX inhibition compared with 100 mg
QD, and thus may help to explain the change in BMD
relative to changes in bone resorption. ONO-5334 SR
can reduce excessive exposure and improve adherence
by reducing dosing frequency from BID to QD. On the
other hand, 300 mg QD was the most effective dose and
regimen for a BMD increase in the OCEAN study, and
had no safety concerns, even though Cmax was 74 times
higher than that required for 99% Emax [16, 17]. In the
current analysis, the antiresorptive effect over 24 h at
300 mg QD almost reached maximum inhibition.
Several cathepsin K inhibitors have been reported [18,
19, 36, 37] and these have different PK and safety pro-
files [18, 25]. However, the maximal effects of drugs in
the same class may not differ [38] and the effect of
300 mg QD ONO-5334 may reflect the maximal effect
of cathepsin K inhibitors on BMD. The maximal BMD
increase with ONO-5334 was not less than that ob-
served for odanacatib at 50 mg once weekly [16, 23].
Fig. 5 Relationships of mean sCTX inhibition over 24 h with observed increases in BMD over 1 year in the OCEAN study [16]. Relationships are
shown for % Emax for sCTX inhibition with increases in (a) lumbar spine (LS1–4) BMD and (b) hip BMD. BMD data in the OCEAN study were
reported by Eastell et al. [16]
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This study has a number of strengths, including use of a
PK/PD analysis to evaluate specific regimens, dose response,
and maximal response in the OCEAN study. However,
there are also several limitations. First, this was a post-hoc
analysis that used data that were not designed for the ana-
lysis. Second, there is a time mismatch between data at
2 weeks after repeated administration in the simulation and
observed 1-year data in the OCEAN study. However, this
mismatch was considered minimal because the antiresorp-
tive effect and PK of ONO-5334 were stable and BMD
gradually increased over 1 year [16]. Third, the inhibitory ef-
fect on osteoblast function, e.g. P1NP, of cathepsin K inhibi-
tors is slightly less than that of bisphosphonates [16]. This is
an important feature of cathepsin K inhibitors, but we used
only antiresorptive effect to simplify the PK/PD analysis.
Conclusion
This study shows that simulation of antiresorptive effect
via sCTX inhibition provides a quantitative prediction of
the dose- and regimen-dependent effects of ONO-5334.
In addition, the analysis clarified the relationship of antire-
sorptive effect over 24 h with BMD increase. The simula-
tion confirmed the observation that a dose of 50 mg BID
is more effective than 100 mg QD (the same total daily
dose) for increasing BMD and suppressing antiresorptive
effect. Thus, simulation of antiresorptive effect over 24 h
permits prediction of the BMD increase induced by
ONO-5334. This is important because sustained release
preparations may have better compliance and maximize
antiresorptive potency using a lower dose of ONO-5334.
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